Early Payer Guidance Across Four Inflammatory Disease Areas

Home / Intelligence / Case Studies / Early Payer Guidance Across Four Inflammatory Disease Areas

Trinity completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas.

Geographic Scope:

Client Situation

The client wanted to gain an in-depth understanding of four inflammatory disease areas to inform early stage decision-making.

Trinity’s Solution

Trinity conducted comprehensive secondary research in the following areas:

  • Disease background including diagnosis, prognosis, epidemiology and unmet needs
  • Current and future paradigm including lines of therapies and standard of care
  • Pipeline analysis including key therapies in development and future treatment gamechangers
  • Pricing and access landscape including pricing analysis, health technology assessment (HTA) outcomes and access status


Four disease-specific early payer guidance reports powered by comprehensive secondary research efforts into disease background, current and future treatment paradigm, pipeline analysis and pricing and access landscape.

Project Outcomes & Impact

Trinity’s comprehensive secondary research and landscape analyses helped the client to make early-stage decisions across therapeutic areas of interest from a future business development perspective.

Related Intelligence


Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future 

Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market […]

 Read More


HTA Vision—Implications Beyond the Rating

June 13, 2024 | 1:00 – 1:45 PM ET

An additional session will be offered on June 18, 2024 at 15:00 – 15:45 CET – Europe/Berlin A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, […]

 Sign Up Now


Rise with the Waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future

Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system. The 2024 PLFSS emphasizes: The direct access scheme is expected […]

 Read More